PDCD1 and hepatocellular carcinoma: The combination of camrelizumab (anti-PD-1) with chemotherapy (FOLFOX4 or GEMOX) showed encouraging preliminary results in 34 treatment-naive HCC patients, with an ORR of 26.5% and a median progression-free-survival (PFS) of 5.5 months [38].